BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study
详细信息 查看全文
- 作者：Tiziana Vavalà ; a ; Alessandro Folladorb ; Marcello Tiseoc ; Domenico Galettad ; Alessandro Morabitoe ; Massimo Di Maiok ; Olga Martellif ; Orazio Caffog ; Pier Luigi Piovanoh ; Diego Cortinovisi ; Nicoletta Zilembol ; Clelia Casartellim ; Giuseppe Luigi Bannan ; Antonio Ardizzoiao ; Maria Luisa Barzellonip ; Alessandra Bearzq ; Giovenzio Genestretir ; Claudia Mucciarinis ; Virginio Filipazzit ; Jessica Menisb ; Elisa Rizzou ; Fausto Barbieriv ; Erika Rijavecz ; Fabiana Cecerex ; Emilio Briay ; Gianluca Spitaleriw ; Antonio Rossij ; Silvia Novelloa ; silvia.novello@unito.it" class="auth_mail" title="E-mail the corresponding author
- 关键词：ESMO ; European Society for Medical Oncology ; ASCO ; American Society of Clinical Oncology ; ECOG ; Eastern Cooperative Oncology Group
- 刊名：Lung Cancer
- 出版年：2016
- 出版时间：May 2016
- 年：2016
- 卷：95
- 期：Complete
- 页码：73-81
- 全文大小：997 K
文摘
- •
EGFR-TKIs first line treatment evidences impressive objectives response rates.
- •
After 9–12 months acquired resistance to EGFR-TKIs arises.
- •
No optimal therapy has been established beyond EGFR-TKIs progression.
- •
This multicenter study describes patients who progressed to EGFR-TKIs.
- •
Treatments, efficacy and safety beyond EGFR-TKIs progression have been described.